The subventricular zone (SVZ) is the largest neurogenic niche in the adult mammalian brain, containing neural stem cells (NSCs) that continuously generate new neurons throughout life. Located along the lateral ventricles, SVZ progenitors give rise to olfactory bulb interneurons and, to a lesser extent, other neuronal populations, making this region crucial for brain plasticity and repair.
SVZ contains distinct cell types arranged in a niche architecture:
- Soma: Small (8-12 μm), elongated or oval
- Processes: Extend toward ventricle and blood vessels
- Primary cilia: Contact cerebrospinal fluid
- Junctional complexes: E-cadherin connections
- Soma: Larger (10-15 μm), round
- High proliferation: Rapid cell division
- Marker expression: Intermediate between B and A cells
- Soma: Small (8-10 μm), elongated
- Chain migration: Travel in chains via rostral migratory stream
- Axonal proteins: Express TAU, MAP2
| Marker |
Cell Type |
Function |
| GFAP |
Type B |
Astrocyte marker, NSC marker |
| NES |
Type B |
Nestin (intermediate filament) |
| EGFR |
Type C |
Epidermal growth factor receptor |
| DLX2 |
Type C |
Transcription factor |
| DCX |
Type A |
Doublecortin (neuroblast marker) |
| PSA-NCAM |
Type A |
Polysialylated neural cell adhesion molecule |
- Olfactory bulb neurons: ~700-1000 new neurons/day in mice
- Interneuron subtypes: GABAergic granule and periglomerular cells
- Circuit integration: New neurons form functional synapses
- Stroke response: Increased proliferation after ischemia
- Migration to damage: Neuroblasts can redirect to injury sites
- Regeneration limits: Limited functional recovery in humans
- Vascular support: Blood vessel contacts
- CSF signaling: Ventricular signaling
- Astrocyte support: EGF and BDNF provision
SVZ neurogenesis is affected in AD:
- Early decline: Reduced proliferation precedes pathology
- Amyloid effects: Aβ inhibits neurogenesis
- Cognitive correlates: New neuron numbers predict memory
- Therapeutic target: Enhancing neurogenesis
SVZ in PD:
- Dopaminergic neurogenesis: Limited to no dopaminergic replacement
- Olfactory dysfunction: Linked to olfactory loss in PD
- Endogenous repair: Attempts to enhance SVZ response
- Cell therapy source: SVZ cells as transplant source
SVZ responds to stroke:
- Proliferation surge: 2-10x increase post-stroke
- Migration to injury: Neuroblasts redirect to damaged striatum
- Differentiation limits: Mainly glial, limited neuronal
- Therapeutic potential: Growth factor enhancement
SVZ cells in tumor biology:
- Glioma origin: May be cells of origin for some gliomas
- Tumor niche: Support tumor growth
- Therapeutic resistance: Treatment-resistant cells
- Reduced proliferation: Decline begins in early adulthood
- Cellular senescence: p16INK4a accumulation
- Niche deterioration: Decreased vascular support
- Microglial activation: Pro-inflammatory cytokines inhibit
- Chronic inflammation: Sustained reduction
- Cytokine effects: TNF-α, IL-6 impair neurogenesis
- Hypoxia: HIF1α role in niche
- Growth factor decline: Reduced EGF, BDNF
- Energy stress: AMPK activation inhibits
| Subregion |
Cell Types |
Function |
| Dorsal SVZ |
Type B, C |
Olfactory neurogenesis |
| Lateral SVZ |
Type B, C |
Major neurogenic zone |
| Ventral SVZ |
Type B |
Adjacent to striatum |
- Growth factor delivery: EGF, BDNF, GDNF
- Small molecule agonists: Enhance proliferation
- Cell transplantation: SVZ-derived NSCs
- Anti-inflammatory: Reduce microglial activation